Gilberto De Lima Lopes, MD, discusses the rationale to stop immunotherapy after 2 years in patients with lung cancer.
Gilberto De Lima Lopes, MD
Advertisement
Articles by Gilberto De Lima Lopes, MD
Gilberto De Lima Lopes, MD, discusses the rationale to stop immunotherapy after 2 years in patients with lung cancer.
Gilberto De Lima Lopes, MD, discusses the FDA approval of nivolumab (Opdivo) and ipilimumab (Yervoy) in non–small cell lung cancer (NSCLC).
Gilberto De Lima Lopes, MD, discusses the standard of care for pembrolizumab in patients with metastatic lung cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Generic Enzalutamide Tablets Granted Tentative FDA Approval for Prostate Cancer
2
The OncFive: Top Oncology Articles for the Week of 6/21
3
Five Under 5: Top Oncology Videos for the Week of 6/21
4
T-DXd Plus Pertuzumab Sets New Treatment and Research Standards in HER2+ Breast Cancer
5